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A B S T R A C T
Background: Transcranial magnetic stimulation (rTMS) may inﬂuence the progression of PD compared with
levodopa. The long term mind modiﬁcation eﬀect of repeated rTMS and tDCS is not known, nor are the pre-
dictors for the eﬀect of NBS.
Objective/hypothesis: We hypothesized that the regularly repeated rTMS would decrease the development of PD.
Later, the treatment protocol was completed with transcranial direct current stimulation (tDCS), supposing that
there is an add-on eﬀect. NBS may diﬀerently inﬂuence motor and mental aspects of the disease.
Methods: Thirty patients with PD were followed for 3.5 years in an open study. They were stimulated with 1 Hz
rTMS every half year for 1.5 years. After that the tDCS was add to the stimulation over both sides of the
cerebellum for the next 2 years. UPDRS, Trail Making Test and dual tests were used. The linear regression lines of
score systems and percentage of yearly increment were counted, analyzed by ANOVA.
Results: The yearly progression rate for UPDRS total was 2% for 3.5 years, 0.6% ≤65 years, 3.6%>65 years.
The increment was around zero during the rTMS+ tDCS stimulations in patients ≤65 years. The slope of the
equation showed the same tendency. The individual sensitivity to the NBS was high. tTMS and tDCS> 65 yrs
improved pathological executive function (p < 0.0001).
Conclusion: The motor ability in PD was maintained at the same level in patients≤65 years with NBS for the 3.5
years in contrast to patients> 65 years. The cognitive function of patients> 65 yrs was favorable inﬂuenced by
rTMS and tDCS. Age is the main predictor of the eﬀect of NBS. rTMS and tDCS can slow the progression of PD
without any side eﬀects but in an age-dependent way.
1. Introduction
Parkinson’s disease (PD) produces progressive declines throughout
the patient’s life. The change in the quality of life is determined by
genes (Hariri et al., 2003; Cheeran et al., 2008; Lipsky and Marini,
2007; Paul et al., 2016; Davis et al., 2016; Escott-Price et al., 2015) and
environmental factors (Simon et al., 2015; Moccia et al., 2016). How-
ever, the environmental factors cannot be strictly separated from ge-
netic abnormalities because they interact (Simon et al., 2017). Pro-
gression of the disease is not linear (Reinoso et al., 2014) and cannot be
eﬀectively inﬂuenced by drugs. The ADAGO study (Olanow et al.,
2009) assumed that rasagiline may reduce the progression rate of PD
but 4 years later this hypothesis has not been conﬁrmed (Rascol et al.,
2016). Furthermore, stimulation of the subthalamic nucleus did not
slow down the progression of PD (Lilleeng et al., 2014). The age-de-
pendency of the progression of the disease was stressed in a follow-up
study for 9 years (Hely et al., 1995). The importance of gender, tremor
dominant subtype and cognitive status deeply inﬂuence the progression
of PD. The appearance of dementia and postural instability predicts the
worsening of PD (Hely et al., 1995; Evans et al., 2011). The progression
rate was diﬀerent in the follow-up studies (Reinoso et al., 2014; Hely
et al., 1995; Di Battista et al., 2016; Liu et al., 2015a, 2015b; Erro et al.,
2016; Pedersen et al., 2017; Mendes et al., 2016). They agreed that the
appearance of non-motor symptoms signiﬁcantly depressed the quality
of life of patients with PD, even if their motor ability was the same (Erro
et al., 2016). Several days of repetitive transcranial magnetic stimula-
tion (rTMS) decreases the Parkinsonian symptoms for months (Málly
et al., 2017; Khedr et al., 2003, 2006) but its long term eﬀect on the
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development of PD is not known. The rTMS as an add-on therapy to
levodopa substitution slowed the progression of Parkinson’s disease,
compared with the group receiving the drug alone (Málly et al., 2004).
However, the long term mind modiﬁcation eﬀect of regularly repeated
rTMS and tDCS is not known. Furthermore, the predictors of the eﬀects
of treatment with non-invasive brain stimulation are not known. By the
end, our long-term follow-up study compared rTMS stimulation with
the rTMS plus tDCS. Motor disability and executive function were stu-
died in the early phase of Parkinson’s disease for 3.5 years.
2. Materials and methods
2.1. Patients
The study was approved by the Regional Ethics Committee of the
Petz Aladár University Teaching Hospital in Győr, Hungary.
Thirty patients with PD in the Hoehn-Yahr I-II stage (Hoehn and
Yahr, 1967) were involved in the study. The demographic data are
included in Table 1. At the baseline, patients did not have postural
instability, dementia, or dyskinesia. Their motor state was steady
during the day. No patient had the tremor dominant form of the disease.
Patients took slow release levodopa with a dopa decarboxylase in-
hibitor and also entacapone in a separate tablet (at the dose
300–600mg/day) (Fig. 5). A dopamine receptor agonist was not used.
All patients with PD reacted well to levodopa. Patients were tested
while taking the drugs. They were examined before the study, at the
end of the stimulation and after one month of non-invasive brain sti-
mulation. The stimulation with rTMS and later rTMS plus tDCS was
repeated every half year for three and half years (Fig. 1).
2.2. The applied methods
The patients were tested with the Uniﬁed Parkinson Disease Rating
Scale (UPDRS) (Fahn and Elton, 1987), a Trail Making Test (Reitan,
1992) and a dual test. The dual test had three parts. The time to walk a
distance of 25m was measured. The measurement was repeated
counting back from 100 by 3 and by 7. We measured the distance a
patient could walk in 6min and the time to walk 10m. A Mini Mental
Rating Scale excluded the patients with dementia from the study. Pa-
tients were tested before the study and then one week, one month and
six months after the rTMS treatment. The examinations were performed
while patients were taking levodopa with dopamine decarboxylase and
cathecol ortho-methyl transferase inhibitors.
2.3. Protocol for stimulation with repetitive transcranial magnetic
stimulation
One-Hertz stimulation was applied over both dorsolateral-prefrontal
cortices (DLPFC) and over the brain stem. Each DLPFC was marked
with an EEG cap. The brain stem was marked 2 cm from the edge of the
occipital bone. The intensity was 25% of the maximum output of the
device (2.3 T) (Magstim 220). The intensity was chosen according to a
dose-response curve where the optimal intensity for treatment in PD
was determined (Málly and Stone, 1999a, 1999b). Fifty stimuli with
25% of 2.3 T were given over each DLPFC. One hundred stimuli with
40% of maximum output were applied over the brain stem. Twelve
sessions were done over 7 days.
2.4. Protocol for stimulation with transcranial direct current stimulation
The stimulator produced by Magstim (HDC stim TM) was used. Both
anodes were placed over the hemispheres of the cerebellum. The
cathode was placed over the middle part of the frontal area. One mA
current stimulation was used for 20min once a day for ﬁve days during
each treatment period.
2.5. Statistical analysis
Results are expressed as the mean± standard deviation of mean
(S.D.) and sample size (N) for each treatment group. The normality of
data was checked by applying the Shapiro-Wilk’s test. When non-
normal data could not be rejected, homogeneity of variances was as-
sessed through the Levene’s test. Means were compared by a t-test or by
separately repeated measurements analysis of variance (ANOVAs) with
Tukey’s correction for multiple comparisons applied where appropriate.
The linear regression analysis was made to show the progression of the
disease with the scatter plot diagram. The slope of the regression line
indicates the progression of the diseases.
The annual increment in percentage was counted. All of the test
scores of patients were given as a percentage of total score and are
presented for each group of patients. These averages were subtracted
from the last value of the followed period. At the end, the average of
these diﬀerences was deﬁned as the annual increment.
The analysis was two-sided, with a level of signiﬁcance of α= 0.05.
All statistical analyses were done using the SAS 9.4 (SAS Institute Inc.,
Cary, NC, USA.) software package.
3. Results
The eﬀect of rTMS and rTMS+ tDCS on the change of the UPDRS
total is demonstrated in Fig. 2. However, there was no signiﬁcant dif-
ference at the baseline between the patients≤65 years and>65 years
but the older group showed higher increases compared to the younger
group of patients. Patients with PD≤ 65 years had minimal
Table 1
Demographic data of patients involved into the study.
Number of
patients (N)
Age in years Gender F/M Education in
years
Duration of the disease
in years
Tremor/
Akinezis
Dose of levodopa at baseline
in mg
Hoehn-Yahr stage
Under 65
years
16 58.6 ± 7.5 1.5 ± 0.5 15.3 ± 3.0 6.2 ± 3.3 1.4 ± 0.5 334.3 ± 184.1 1.31 ± 0.58
Above 65
years
14 72.1 ± 3.8 1.0 ± 0.2 16.5 ± 1.3 4.6 ± 3.4 1.4 ± 0.5 321.4 ± 191.8 1.53 ± 0.49
Fig. 1. Protocol of the treatment. Patients (N= 30) were followed for 3.5 years.
From −18 months to the 0 point; they got repetitive rranscranial magnetic
stimulation (rTMS).The parameters of rTMS were as follows: 1 Hz, 25% of 2.3 T
over the dorsolateral prefrontal cortex (DLPFC) 2×50 stimulus and 1 Hz 40%
of 2.3 T 100 stimulus over the brainstem (Magstim 220). At the zero point,
transcranial direct current stimulation was added to rTMS. Anodal stimulation
was applied over both hemispheres of the cerebellum with 1mA for 20min. The
cathode was placed over the middle part of the frontal area.
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deterioration, which became signiﬁcant after 2.5 years compared to
their values at baseline but later they did not show any signiﬁcant
deterioration. Patients with PD > 65 years revealed a graduated
worsening over years, which became signiﬁcant after 36 months
(p < 0.001). The deterioration was also maintained over 42 months
(p < 0.001). The development between the two age groups of patients
diﬀered signiﬁcantly at the point of “0”when the tDCS was added to the
rTMS. The signiﬁcant diﬀerence was maintained between the two age
groups for the next two years. The UPDRS motor scores of the two
groups did not signiﬁcantly diﬀer. Otherwise values at baseline and at
the end of 42 months were in the same range. However, a high standard
deviation was observed on each occasion when they were tested in-
dicating that there is a great individual sensitivity to the stimulations.
The side eﬀects of levodopa therapy were included in the Table 2.
The development of PD with NBS was analyzed by linear regression
lines, where the correlation coeﬃcient and the slope of the equation
were given during diﬀerent stimulation periods. The correlation coef-
ﬁcient of the UPDRS total and the motor score of UPDRS did not show
any correlation with time. The correlation coeﬃcient was not sig-
niﬁcantly diﬀerent from the time. That is why we took into account the
slope of equation, which accurately reﬂected the progression of the
disease. For the whole follow-up period (42 months) (N=30) the slope
of the equation was 0.17992. The slope of the equation diﬀered in the
two age groups counted for the whole follow-up period (Fig. 3. ≤65
years: 0.12510,> 65 years: 0.23190). The patients> 65 had a greater
deterioration than the younger patients for 3.5 years (Fig. 3). The two
treatment periods were separated. There was no great diﬀerence during
the administration of rTMS (−18 to 0 months) between the patients in
their equation. Patients ≤65 yrs: y= 16.934+0.21039 * Time cor-
relation: r= 0.22907 p=0.3933; patients> 65 years :
y= 22.116+0.25261 *Time, correlation: r= 0.18538 p=0.5257.
When tDCS was added, the slope of the regression line for patients≤65
years was 0.06814 (Fig. 4). tDCS signiﬁcantly slowed the progression of
PD≤ 65 years. We do not know if this was an add-on eﬀect of rTMS or
the eﬀect tDCS alone. rTMS plus tDCS produced a slope of equation:
0.31045 for patients> 65 years (Fig. 4). None of the stimulations
slowed down the progression of PD in patients> 65 years. We sum-
marized the progression rates in percentage of diﬀerent treatment
periods (Table 4). The rTMS plus tDCS for two years showed the zero
progression rate in the patients ≤65 years, which overlapped the
analysis of regression lines. The patients> 65 years had a much lower
progression in UPDRS motor scores under the dual treatments than with
the administration of rTMS alone. The diﬀerent methods showed dif-
ferent progression rates (Table 4).
The linear regression line of their motor scores was nearly zero in
both groups of patients However, the standard deviation was extremely
high. It reﬂects a great variation among individuals in their sensitivity
to NBS. As the disease progresses, higher doses of levodopa are re-
quired. In this study the average dose of levodopa was between
300–450mg/day, which was nearly stable during the research (Fig. 5).
The side eﬀects of levodopa therapy developed at the end of the fol-
lowed period (Table 3). Dyskinesia was twice as frequent in the younger
group of patients as in the older ones. However, it conﬁrmed a good
reaction to levodopa. Postural instability (12–21%), and a freezing ef-
fect (12–14%) rarely appeared but was in equal proportion in both
groups at the end of the study (Table 4). Dementia was not observed.
Fatigue and depression appeared in 31% of the younger group and 21%
of the older group.
The executive function was tested with a Trail Making Test (B-A)
(TMT) and dual tests. The executive function assessed by TMT showed
no progression (according to regression lines) in age-matched healthy
controls (N= 26). Patients with PD≤ 65 years had a slight deteriora-
tion over years y= 16.113+ 0.12510 * time.
The group>65 years signiﬁcantly diﬀered from age-matched
healthy controls in their mental achievement at the baseline assessed by
TMT B-A (control: 46 ± 11 s, PD: 61 ± 10 s p < 0.05). They showed
slow, but signiﬁcant improvement over the 3.5 years (Fig. 6). The dual
tests showed the same tendency as TMT. The slope of equation was
y= 65.576–0.3302*Time in patients> 65 years in the dual test
counting back by 3, and the test counting back by 7
y= 94.820–0.4333**Time.
4. Discussion
Lately, many long-lasting observations of patients with PD have
been published (Hely et al., 1995; Reinoso et al., 2014; Ding et al.,
2016; Kojovic et al., 2015; Di Battista et al., 2016; Mendes et al., 2016;
Erro et al., 2016; Pedersen et al., 2017). Our present study demon-
strated a favorable inﬂuence of regularly repeated non-invasive brain
Fig. 2. The progression of Parkinson’s disease
assessed by UPDRS total (N=30). Data are
given in mean ± SD. The ﬁlled black columns
represent patients ≤65 years (N=16), the
dotted columns show patients> 65 years
(N=14). In every half year (from−18 months
to 0) they got rTMS with 1 Hz low intensity for
7 days. At the 0 point, tDCS was added to rTMS.
The progression of patients> 65 years re-
vealed a non-linear progression. The progres-
sion became signiﬁcant, compared to the
baseline in the 3rd year (∗ = p < 0.001). The
patients ≤65 years showed a diﬀerent pattern.
They became signiﬁcantly worse 2.5 years
latter (+ = p < 0.05) compared to the base-
line, but their state was equilibrated during the
3.5 follow-up years. There was a signiﬁcant
diﬀerence between the two groups from the
zero point.
Table 2
The side eﬀects of levodopa at the end of the study. Dyskinesia was higher in
the younger group.
≤65 >65
N=16 N=14
Dyskinesia 8 3
Wearing oﬀ 5 4
on-oﬀ 4 3
hallucination 0 1
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stimulation on the progression of the disease. This is the ﬁrst observa-
tion which suggests that beyond the symptomatic eﬀects, NBS aﬀects
the progression of PD in an age-dependent way. Both the motor and
mental functions of patients with PD were tested in this study, although
those functions reacted diﬀerently to rTMS and tDCS. The total score of
UPDRS, motor score of UPDRS and ADL showed diﬀerent rates of
progression of PD during the distinct stimulations (Table 4) reﬂecting
similar observations by Klawans (1986). According to his results, the
symptoms of PD progressed diﬀerently over 12 years. The same out-
come was produced with electrophysiological measurements evaluated
by paired associative stimulation, a silent-period, short-interval in-
tracortical inhibition for one year in 12 patients. There was a great
variation in the progression of values and correlation of electro-
physiological parameters and motor changes. Therefore the impact of
individual progression was stressed (Kojovic et al., 2015). The authors
of both papers concluded that individual analysis is better than a group
analysis.
The UPDRS total includes the Activities Daily Living (ADL) sub-
score, which may be one of the best markers for indicating the impact of
the progression rate in patients with PD opposite to their motor scores
(Harrison et al., 2009). After NBS, the UPDRS motor scores of the pa-
tients changed more than their ADL score. While their ADL of patients
≤65 years was signiﬁcantly changed, there was no convincing decrease
in the subjects> 65 years. Altogether the patients> 65 years had a
higher progression rate (assessed by their UPDRS total) than the
younger group. In spite of faster deterioration in these cases, under the
dual stimulations, their progression rate did not reach the published
percentage. The yearly increment was 2.1% in their UPDRS total scores
and 1.3% in UPDRS motor scores in the present study. In previous
publications, the progression rate in percentage revealed a great
Fig. 3. The eﬀect of rTMS and tDCS on Parkinsonian
Symptoms assessed by UPDRS total. Patients ≤65 years
(N=16) (represented by a linear line) and patients> 65
years (showed by a dotted line) were followed for 3.5
years. rTMS with 1 Hz from −18 months to the 0 point
was given. At this time the tDCS was added to the treat-
ment every half year. Description of linear regression line
≤65 years: y= 16.113+ 0.12510 ∗ Time, regression
line> 65 years: y= 21.743+ 0.23190 * Time.
Fig. 4. The eﬀect of rTMS and tDCS on Parkinsonian
Symptoms assessed by UPDRS totals. Patients ≤65 years
(shown by a continuous line) (N=16) and> 65 years
(represented by a dotted line) (N=14) were followed for
2 years. rTMS with 1 Hz and the tDCS were given every
half year. Description of linear regression line ≤65 years:
y= 17.0032+0.0632*Time;> 65 years y= 22.0802
+ 0.2159*Time. The ability of patients under 65 years to
move was stable during the followed period, while that of
patients above 65 years worsened.
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variation. The yearly increment ranged between 1.2% and 3.8% de-
pending on the applied scores (Mendes et al., 2016). They conﬁrmed in
their study that the diﬀerent progression rates belonged to diﬀerent
Parkinsonian symptoms. In our previous study, where the yearly in-
crement was 2.8% in the group receiving levodopa alone, the group
treated with levodopa plus rTMS there was a 0.94% progression in non-
selected patients (Málly et al., 2004). Other authors found the following
results. A study by Alves et al. (2005) reported an average motor score
of 3.1%, ADL of 3.5%, and nearly the same results were presented by
Louis et al. (1999), who published an annual score of 3.6%, with sub-
scores of 2–3.1 % (Alves et al., 2005; Louis et al., 1999). Diﬀerent re-
sults were published by Reinoso et al. (2014) whose patients had
UPDRS motor scores from baseline ranging from 0.62% to 3.67%. An-
nual decline in the total score of UPDRS was 1.34 (on-phase) and an-
nual decline: 1.38 in the oﬀ-phase was reported by Jankovic (Jankovic
and Kapadia, 2001). However, the slope for total scores was 2.97 and
1.38 for motors scores, which is much higher than our presented data.
This diversity of results may come from the arrangement of the studies
because patients with diﬀerent severity of PD were collected for a long
term observation; furthermore the length of time of the follow-up of
patients varied between 3 and 8 years (Jankovic and Kapadia, 2001).
The progression rate was higher at both the onset of the disease and in
the late phase of the disease (Lee et al., 1994; Schrag et al., 2007;
Maetzler et al., 2009). In the late stage of PD, postural instability and
dementia appear frequently, which are probably resistant to levodopa
treatment (Hely et al., 2005, 2008; Ding et al., 2016). At onset of the
disease, the progression of motor disability is faster (Ding et al., 2016).
The yearly increment was 2.3% in the oﬀ-phase published by Ding et al.
(2016). There was a 4 year follow up study of 124 patients in the late
phase of their disease. One of the studies published motor and disability
scores which ranged from 2.4 to 7.4% per year (Schrag et al., 2007).
In this study, we evaluated patients in the middle phase of their
disease. They were involved in the experiment when they had their
symptoms for nearly 6 years and they were examined at least 10 years
after the onset of their disease. This period of 3.5 years may cover the
middle period where the progression of the disease was steady. We
restricted the variability of progression by eliminating patients with
dementia or postural instability; we included only the Hoehn-Yahr I-II
stages with a similar duration of the disease. In spite of the small
number of patients in the two homogenous groups (which diﬀered only
in age), we can prove a favorable eﬀect of rTMS and rTMS+ tDCS on
the progression of PD. The slopes of the equations were nearly zero
during the administration of rTMS+ tDCS, assessed by UPDRS totals
and their motor scores in the group≤65 years, which was conﬁrmed by
counting the percentage of the annual increment. None of the published
studies demonstrated this low progression rate as in our study with
NBS.
The studies endeavored to determine the predictive signs of the
progression of the disease. In the following paragraphs we will discuss
the impact of daily activity, gait imbalance, the role of levodopa ad-
ministration on the progression rate, and examinations in on-oﬀ phases.
Furthermore, we will consider the age of patients when they were in-
volved in the treatment, and discuss the eﬀect of their cognitive ability
on the progression of PD.
One of the studies emphasized that the Activity of Daily Living
(ADL) was a good prognostic factor to estimate the progression of the
disease (Harrison et al., 2009). We discussed it above in detail with our
results.
The other predictive symptom in the progression of Parkinson’s
disease was the gait imbalance (Ellis et al., 2016; Williams-Gray et al.,
2013). The impact of the gait/postural stability was also stressed with
factor analysis (Evans et al., 2011). Symptoms collected in one factor
tended to progress inexorably with time but they did not correlate with
each other in their development through time. It seemed that it was one
of the causes of observed heterogeneity of PD. The onset of postural
instability is important in the prognosis of PD (Evans et al., 2011). It
was conﬁrmed that a gait/balance disorder was a better predictor than
the early presence of tremor (Hershey et al., 1991). In our study over
3.5 years, the appearance of signs of the progression of the disease was
also revealed. Postural instability appeared in two cases≤65 years and
three cases> 65 years at the end of the follow-up study, when the
duration of the disease had been about 10 years in both groups of pa-
tients. We counted the percentage of symptoms. It was 12–21 % for
postural instability in the two age groups and 12–14% for the freezing
Fig. 5. Change in the dose of levodopa during the followed 3.5 years. Data are
given in mean ± SD. The black columns represent the patients≤65 years and
the dotted columns show the subjects> 65years. Patients were treated with
repetitive transcranial magnetic stimulation (rTMS) with 1 Hz for 7 days every
half year (from −18 to 0). During the next 2 years the rTMS and transcranial
direct current stimulation (tDCS) were given together every half year. There
was no signiﬁcant change in the dose of levodopa. The standard deviation was
high.
Table 3
The progression of the severity of symptoms at the end of the study. Dementia
was not appeared at the end of the study. Postural instability appeared only in
few cases by the end of 10 years.
≤ 65 >65
N=16 N=14
postural instability 2 3
freezing eﬀect 2 2
fatigue 5 3
depression 5 4
dementia 0 0
Table 4
Annual increments in percentage.The values separately show the UPDRS total
scores, Activity of Daily Living (ADL), and UPDRS motor scores in percentage
counted in yearly increments. The horizontal columns diﬀerentiate between the
treatment periods. The patients (N=30) were separated according to their age.
The lowest progression was detected in patients ≤ 65 years who had the
combination of rTMS+ tDCS for two years.
UPDRS Total ADL UPDRS Motor
All of the patients
3.5 years N=30 2.0 2.8 0.6
≤65 years N=16 0.6 −0.5 −0.3
> 65 years N=14 3.6 6.5 2.8
All of the patients
−18 to 0 months rTMS 1.8 1.6 1.8
≤65 years N=16 1.4 1.6 1.4
> 65 years N=14 2.3 1.7 2.3
All of the patients
0–24 months rTMS+ tDCS 0.8 0.6 −0.6
≤65 years N=16 −0.3 −1.4 −0.3
> 65 years N=14 2.1 5.1 1.3
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eﬀect. We may suppose that the rTMS stimulations over the brain stem
and tDCS over both hemispheres of the cerebellum played a role in
these favorable eﬀects.
The cerebellum also takes part in the motor and mental circuits
(Schniepp et al., 2017; Mentis et al., 2003). Its important role in Par-
kinson’s disease was reviewed by Wu and Hallett (2013). It is empha-
sized that the gait disturbance, which is the cardinal symptom of PD,
may be caused by the hypoactivation of the anterior lobe of the cere-
bellar hemisphere, hyperactivation of the cerebellar vermis and also the
activation changed in many other brain regions assessed by single-
photon emission computed tomography (PET) (Hanakawa et al., 1999).
The potential role in the freezing of the function of the pedunculo-
pontine nucleus was highlighted in the brain stem (Schweder et al.,
2010; Fraix et al., 2013). We can summarize that the cerebellum plus its
connections and the brain stem have a pathological role in the symp-
toms of PD. We stimulated these regions by rTMS with 1 Hz and anodal
tDCS. However, we can not distinguish between the eﬀects of the two
stimulations; we suppose that the reduction of postural instability and
freezing eﬀect may come from the dual stimulation over the cerebellum
and the brain stem. Stimulations over the cerebellum can modulate the
intracortical primary motor cortex activity (Fierro et al., 2007), which
may further have an add-on mechanism for the healing eﬀect of NBS
over the cerebellum. Our results coincide with other outcomes after
stimulation of the cerebellum. The therapeutic eﬀect in alleviating
resting tremor was published by (Lefaivre et al., 2016) and relieving
gait ataxia was described by (Manto and Ben Taib, 2008; Bonni et al.,
2014). Stimulations over the cerebellum were reviewed by other re-
searchers (Grimaldi et al., 2016; Franca et al., 2017).
However, fatigue and depression reached 30% in both age groups.
We did not observe dementia at the end of the study. In spite of the
small number of patients, these are very important observations, be-
cause the quality of life is extremely worsened when non-motor
symptoms appear, mainly dementia and postural instability (Hely et al.,
1999). According to a 4 year longitudinal study, the appearance of non-
motor symptoms signiﬁcantly increased over time (Erro et al., 2016),
like diﬃculty in swallowing, sleepiness, restless legs syndrome, and
hallucinations (Maetzler et al., 2009). Dopamine therapy has a little
impact on them.
Although treatment with levodopa has been used for 50 years and it
has a good symptomatic eﬀect in PD, its eﬀect on the development of
Parkinson’s disease has not been conﬁrmed (Hely et al., 1999; Fahn
et al., 2004). However, in a double-blind study with diﬀerent doses of
levodopa for 42 weeks (ELLDOPA) after the wash-out period which
lasts for 2 weeks, the group treated with a high dose of levodopa
showed a better state assessed by their UPDRS total scores than the
placebo group (Parkinson Study Group, 2004). This raises the possibi-
lity that levodopa has an eﬀect on the progression of PD but the long
term favorable symptomatic eﬀect cannot be excluded because the ef-
fect of levodopa may persist for two weeks during the wash-out period.
It takes 32 days to eliminate 90% of the drug (Hauser and Holford,
2002). It seems that the tenth “anniversary” is very important in the life
of patient with PD. The motor symptoms get better or are maintained
for nearly ten years but the quality of life steadily deteriorates. Hoehn
and Yahr (1967) indicated that within the ﬁrst 10 years there is no
diﬀerence between the patients under 50 years and over 50 years.
According to Reinoso et al., (2014) during the ﬁrst 6.5–7 years, the
progression rate was lower, assessed by UPDRS motor scores, but later
it increased (between 0.62 and 3.67%). The progression of the disease
without levodopa was studied in Africa (Cilia et al., 2014). Their con-
clusion was that motor ﬂuctuation and dyskinesia are not associated
with the duration of treatment with levodopa, even with a longer
duration of the disease and a higher levodopa dose (Cilia et al., 2014).
No clinicopathological study could conﬁrm the eﬀect of levodopa on
the progression of the disease. Ninty-seven patients were studied after
their deaths. The study showed that there was no diﬀerence in the Lewy
body and other pathologies between the dopa responsive and non-
responsive cases. The pathological changes varied according to the age
and duration and manifestation of disease independently of the pa-
tient's response to dopa.(Kempster et al., 2007). In our study, the le-
vodopa dose was not increased during the NBS treatment period. Fur-
thermore, the daily administration of levodopa did not diﬀer
signiﬁcantly between the two age groups. The same observation was
made in our earlier study that patients treated with regularly repeated
rTMS needed a lower dose of levodopa compared with patients treated
with levodopa alone (Málly et al., 2004). It is a very important ob-
servation that during the administration of NBS, the dose of levodopa is
nearly steady. It is well known that the side eﬀects of levodopa depend
on the dose of drug. During NBS treatment, the dose of levodopa can be
reduced, which decreases the side eﬀects. In our study the dose of le-
vodopa was not signiﬁcantly changed over the 3.5 years. We concluded
that the rate of progression could not be inﬂuenced by levodopa. In all
of the progression studies, the gold standard levodopa therapy was
given. This way we can compare those studies with our long term
follow up study.
The examination during the time the drug was having an eﬀect or
withdrawal from it impacts the judgment of the progression of PD.
Fig. 6. The eﬀect of rTMS and rTMS+ tDCS on Parkinsonian symptoms assessed by Trail Making Test (TMT)> 65 years (N=14). Steady improvement was
observed mainly after the rTMS and tDCS. The description of linear regression line: y= 51.447–0.5600 ∗ Time, correlation: r = −0.2539 p = 0.3810.
J. Málly et al. Brain Research Bulletin 142 (2018) 78–87
83
Downloaded for Anonymous User (n/a) at HUNGARY - University Semmelweis Med from ClinicalKey.com by Elsevier on April 08, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.
Recently, Ding et al. (2016) indicated that the test of patients in the oﬀ-
phase reﬂected the real progression of the disease. However, there is no
pure drug-free period in patients who are regularly treated with levo-
dopa. The progression continues in both phases of the on-phase and the
oﬀ-phase (Ding et al., 2016; Mendes et al., 2016). In our study the
patients were tested in the drug active phase of the day.
The age-dependency of patients was studied widely in the literature.
The onset of disease in older age was associated with a faster progres-
sion of PD (Hely et al., 1995; Alves et al., 2005; Reinoso et al., 2014;
Spica et al., 2013; Wickremaratchi et al., 2009; Levy, 2007; Diederich
et al., 2003; Post et al., 2011). The prognostic factor of the age at onset
for future motor impairment was highlighted by Post et al. (2007). They
declared that the lower age at baseline of the study was related to a
slower progression rate. However, dystonia and dyskinesia appeared
more frequently in the younger age group of patients than those at
onset at an older age (Wickremaratchi et al., 2009). Our study conﬁrms
this observation, because in the younger group of patients, dyskinesia
was present twice as frequently as in the older group of patients.
This means that they reacted well to levodopa. In agreement with
the literature, the younger group progressed more slowly in our study,
too. The progression was slower and it stopped during the rTMS plus
tDCS stimulation for two years. We concluded that NBS yields better
eﬀects in the group ≤65 years than for the older group of patients.
However, the eﬀect of NBS on the progression in motor scores> 65
years cannot be excluded.
Diﬀerent eﬀects of rTMS and rTMS plus tDCS on motor disability
and executive function were observed in this study. A strong age-de-
pendency was detected in the total scores of UPDRS. Furthermore, the
rTMS plus tDCS together may have a more signiﬁcant eﬀect in the
development of the disease, according to the value of the slope and the
percentage of yearly increment in the younger group of patients. It was
demonstrated that rTMS was less eﬀective in the group>65 years than
in the younger group of patients over a long time. This observation is
consistent with the observation that the symptomatic eﬀect of rTMS
lasted for a shorter time in the higher age group at baseline (Málly
et al., 2017).
Cognitive deterioration and appearance of dementia are prognostic
factors for a faster progression rate in PD (Marras et al., 2002; Post
et al., 2007). The older age at onset of motor and non-motor symptoms
and dementia are related to each other (Auyeung et al., 2012; Poewe,
2009). Cognitive decline gradually advances over time reported by Di
Battista et al. (2016) based on a 5-year follow-up study. Thirty-nine
percent of patients with PD (N=54) had a reduced cognitive reserve
after 5 years. In their study, the younger aged patients had better
cognitive stability, although the individual diﬀerences were empha-
sized in this paper. How mild cognitive impairment progresses to de-
mentia was examined by Pedersen et al. (2017). They found that after 5
years, nearly 40% of patients suﬀered from dementia.
According to these disappointing results, our observations are very
interesting for the future treatment of PD. The executive function in
patients> 65 years had pathological results which improved gradually
by rTMS and rTMS plus tDCS treatment for 3.5 years. It may be argued
that the patients might learn the tasks, but in contrast, the younger
group of patients showed a slower deterioration of executive function,
assessed by TMT. The patients with age-matched healthy controls
showed a permanent achievement in their tests during the examined
period. According to these observations, we may strongly suppose that
the recovery in the restoration of executive function with NBS from
pathological values (assessed by TMT and dual tasks) is very promising
with respect to future treatments with NBS. We suggest that this new
observation with NBS treatment is not a rapid eﬀect; however it is a
result of a long term repeated treatments. The improvement was ob-
vious only in the pathological values of executive functions in pa-
tients> 65 years, but the younger group ≤65 years revealed a slight,
steady worsening, assessed by TMT over the followed 3.5 years.
However, we cannot determine which kind of stimulation is responsible
for this eﬀect; whether it relates only to the tDCS stimulation or if it is
an add-on eﬀect of rTMS. This favorable eﬀect in patients> 65 years
was continuously shown during both treatments with rTMS and rTMS
plus tDCS. There are publications with tTMS and tDCS stimulations
indicating improving cognitive function (Rektorova et al., 2005; Cotelli
et al., 2006; Antal et al., 2004a, b; Floel et Cohen, 2007; Jahanshahi and
Rothwell, 2000; Ilieva et al., 2018; Kavanaugh et al., 2018). The
comparison of single with repetitive sessions of stimulations for days
with NBS was summarized lately by Buch (Buch et al., 2017).
Diﬀerent protocols were published with NBS in the treatment of PD
(Málly et Stone, 1998; Málly and Stone, 1999a, 1999b; Khedr et al.,
2003, 2006; Lomarev et al., 2006; Lefaucheur et al., 2014; Brys et al.,
2016; Dragasevic et al., 2002; Shirota et al., 2013; Li et al., 2015; Pál
et al., 2010). We do not think that there is only one optimal protocol for
the treatment of PD. We suppose that the frequency and intensity are
connected with each other. Probably the low frequency is connected
with low intensity and high frequency with high intensity as we have
discussed previously (Málly et al., 2017). There are diﬀerent packages
of optimal parameters with frequency, intensity, and duration of sti-
mulation working together may each be eﬀective in the treatment with
NBS. In this way it may be supposed that there may be more than one
package for the treatment of Parkinsonian symptoms, but only 1 Hz
rTMS with low intensity achieved the reduction of development of PD.
This protocol not only improves the Parkinsonian symptoms, but the
progression of disease has been slowed by the repeated rTMS and rTMS
plus tDCS with reduced parameters. The treatment with extremely low
intensity was applied in experimental encephalitis with success
(Medina-Fernandez et al., 2018).
There are several crucial questions are: (a) which kind of re-
generation mechanisms contribute to slowing the speed of PD pro-
gression. We cannot answer it directly. According to animal studies, the
regeneration processes are based on the elevation of brain derived
nerve factor (BDNF) (Müller et al., 2000; Cheeran et al., 2008; Antal
et al., 2010) and the increased production of progenitor cells (Arias
Carrión, 2008; Guo et al., 2014; Ueyama et al., 2011; Liu et al., 2015a,
2015b; Luo et al., 2017). Stimulation with 1 Hz was compared with
30 Hz of stimulation in the brains of adult mice (Abbasnia et al., 2015).
The eﬀect of 1 Hz stimulation started earlier, and more cells were
produced than from the stimulation with 30 Hz. Both stimulation levels
increased the diﬀerentiation of stem cells. However, the change in the
brain plasticity was stressed in the literature after the acute, short sti-
mulations for days but this change lasts for a short time (Hassanzahraee
et al., 2018, reviewed by Huang et al., 2017). The dopamine level in the
striatum is elevated after 1 Hz or higher frequency stimulations, which
explains the symptomatic eﬀects of rTMS. It may overlap the stimula-
tion period and it does not last for a longer time than the stimulation
(Strafella et al., 2001, 2005). The much more interesting aspect of the
focal stimulation is its inﬂuence over the whole brain assessed by stu-
dies of microcirculation (Park et al., 2017) and EEG (Chung et al.,
2015). Neither drugs nor electric stimulations have this special eﬀect as
the rTMS, which may involve non-synaptic connections. The remote
eﬀect of rTMS after focal stimulation may induce a non-synaptic
transmission mechanism: transmitters are released into the extra-sy-
naptic space. This eﬀect was ﬁrst published by Vizi (Vizi, 1984; Vizi
et al., 2010, 2000, 1993, 1981; Vizi and Burnstock, 1988). The acti-
vation of widespread areas of the brain from the focal stimulation ex-
plains the variation of observed eﬀects after the stimulation of the
primary motor cortex and DLPFC. However, this site of actions can not
explain the long lasting remodeling of the brain.
In the last several decades, in in vitro experiments using micro-
perfusion system ﬁeld stimulation have been used at various fre-
quencies to study the release of various transmitters from slice pre-
parations of the cerebral cortex (Vizi and Burnstock, 1988; Vizi et al.,
1989; Matko et al., 1994), hippocampal (Lorincz et al., 2016) striatal
(Milusheva et al., 1996) and spinal cord (Umeda et al., 1997; Sircuta
et al., 2016; Borbely et al., 2017; Vegh et al., 2017). This method made
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possible to study the interaction between diﬀerent axon terminals and
presynaptic eﬀects of drugs and provided convincing evidence that the
release of transmitters from neuronal networks is frequency dependent
and at high frequency (> 10Hz) the release is able to escape from
presynaptic, hetero- and autoreceptor-mediated modulation (Knoll and
Vizi, 1971). In our previous paper (Mally, 2013; Málly et al., 2017) we
started that the non-invasive stimulation (rTMS and tDCS) have fre-
quency-dependent eﬀects on Parkinsonian patients. Nevertheless, in the
literature the available data are rather contraversial (Elahi et al., 2009;
Chou et al., 2015; Wangle et al., 2016 and Zhu et al., 2015) as far as the
frequency of stimulation is concerned. Therefore we conclude that the
eﬀect of transcranial stimulation may depend not only on the fre-
quency, but also on the intensity [U/d (V/mm)] of stimulation, as it is
in in vitro pharmacological experiments. Accordingly, the mode of ac-
tion of non-invasive stimulation is to restore functional connectivity
among neurons (networks).
At present, we can raise the possibility that there is elevated BDNF
and increased production of progenitor cells after the stimulations by
rTMS and tDCS, which may play a crucial role in the slower progression
of the disease. They may not be responsible for the symptomatic eﬀects
of rTMS and tDCS, but they may restore brain connections or networks
for a certain time. Although, it is proved that rTMS increases both the
BDNF and progenitor cells which are interconnected, their long eﬀect
on regenerating processes may need to be proved in the near future.
5. Conclusions
In this study, we conﬁrmed the eﬀect of the low intensity, low
frequency, regularly repeated rTMS and further the combination of
rTMS and tDCS on the progression of Parkinson’s disease. This eﬀect of
NBS was age-dependent and diﬀerently inﬂuenced motor and mental
functions. The progression rate of motor disability diﬀered from the
ADL and the total score of UPDRS. A nearly zero progression in motor
disability was observed during the rTMS plus tDCS stimulations in pa-
tients ≤65 years, in contrast to the patients> 65 years. NBS cannot
only inﬂuence symptoms of PD but also decrease the progression of PD.
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